Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2013; 34(03): 199-203
DOI: 10.4103/0971-5851.123741
ORIGINAL ARTICLE

Report of chronic myeloid leukemia in chronic phase from Ashirwad Hematology Centre, Mumbai, 2002-2009

M G Agarwal
Department of Haematology-Oncology, Ashirwad Haematology Centre, Dadar, Mumbai, Maharashtra, India
,
Usha M Agarwal
Department of Haematology-Oncology, Ashirwad Haematology Centre, Dadar, Mumbai, Maharashtra, India
,
Shonali S Rathi
Department of Haematology-Oncology, Ashirwad Haematology Centre, Dadar, Mumbai, Maharashtra, India
,
Sangeeta Masurkar
Department of Haematology-Oncology, Ashirwad Haematology Centre, Dadar, Mumbai, Maharashtra, India
,
Bindi Zaveri
Department of Haematology-Oncology, Ashirwad Haematology Centre, Dadar, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

We have analyzed our experience regarding use of tyrosine kinase inhibitors especially imatinib mesylate in patients of chronic myeloid leukemia-chronic phase over last 7 years at our center (2002-2009). The object was to report long-term efficacy (hematological, cytogenetic and molecular) and toxicity. Overall, 775 patients were treated. Out of these, 576 were analyzable with a median follow-up of 3.6 years. The median age was 42 years. Complete cytogenetic response (CCyR) was achieved in 351/576 patients, i.e., 62.1%. Grade 3/4 adverse effects were observed in 36 patients, i.e., 6.25%. Age under 40 years, low Sokal score, complete hematological response and CCyR were significant predictive factors for event free survival (EFS) on univariate analysis while low Sokal score and early chronic phase were significant predictive factors for EFS on multivariate analysis. Our results are almost similar to those reported from various studies from western population.

Keywords

Chronic myeloid leukemia - cytogenetic response - imatinib mesylate - India - molecular response - toxicity


Publication History

Article published online:
19 July 2021

© 2013. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-21.
  • 2 O′Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004.
  • 3 Druker BJ, Guilhot F, O′Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.
  • 4 Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004;103:2284-90.
  • 5 Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W, et al. Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. Int J Hematol 2009;89:445-51.
  • 6 Deshmukh C, Saikia T, Bakshi A, Amare-Kadam P, Baisane C, Parikh P. Imatinib mesylate in chronic myeloid leukemia: A prospective, single arm, non-randomized study. J Assoc Physicians India 2005;53:291-5.
  • 7 Hay J, Bapsy PP, Babu KG, Loknatha. Imatinib mesylate in newly diagnosed patients with chronic myeloid leukaemia. ASCO annual meeting proceedings. J Clin Oncol 2007;25:17251.
  • 8 Rajappa S, Varadpande L, Paul T, Jacob R, Digumarti R. Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country. Leuk Lymphoma 2008;49:554-8.